ResearcherScience for Life LaboratoryActive in the last 2 years

Angelica Loskog

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8583-6138; OpenAlex author ID A5063027590. Sources: ClinicalTrials.gov.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 2
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper, 1 trial · 2017: none · 2018: 1 trial · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

Trials 2

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer Study chair NCT03225989 ↗
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer Study chair NCT02705196 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Emma Eriksson · 2 shared papers, 2016–2024 · strength 0.24
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
- Paper Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. DOI 10.1186/s12967-016-1037-z ↗
Gustav Jörgen Ullenhag · 2 shared papers, 2016–2024 · strength 0.24
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
- Paper Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. DOI 10.1186/s12967-016-1037-z ↗
Linda C. Sandin · 2 shared papers, 2014–2024 · strength 0.22
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
- Paper Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. DOI 10.4161/onci.27614 ↗
Ann Marie Leen · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Eric Keith Rowinsky · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Mohamed O. Othman · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Brandon George Smaglo · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Benjamin Musher · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Sara M. Mangsbo · 1 shared paper, 2014 · strength 0.05
- Paper Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. DOI 10.4161/onci.27614 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.